Expression of milk fat globule epidermal growth factor-VIII may be an indicator of poor prognosis in malignant melanoma

J. Oba, Y. Moroi, T. Nakahara, T. Abe, A. Hagihara, M. Furue

    Research output: Contribution to journalArticle

    17 Citations (Scopus)

    Abstract

    Summary Background Milk fat globule epidermal growth factor-VIII (MFG-E8) is a secreted protein that binds phosphatidylserine and promotes apoptotic cell ingestion by phagocytes, mediating the immune tolerance and maintenance of homeostasis. A recent study has shown that MFG-E8 expression in human melanoma is increased with tumour progression; however, the effect of its expression on patient survival has not yet been clarified. Objective To analyse MFG-E8 expression in melanoma, and to determine whether it can serve as a marker for diagnosis, tumour progression and/or prognosis. Methods MFG-E8 expression was examined by immunohistochemistry in 60 primary melanomas, 22 metastatic lesions and 30 benign naevi. The following clinicopathological variables were evaluated: age, gender, histological type, tumour site, Breslow thickness, Clark's level, the presence or absence of ulceration and tumour-infiltrating lymphocytes, and survival periods. Statistical analyses were performed to assess associations and melanoma-specific survival. Results MFG-E8 expression was significantly higher in primary and metastatic melanoma than in naevus. Furthermore, it increased according to tumour progression and metastasis. Patients with MFG-E8 expression in primary tumours had significantly shorter survival periods than those without MFG-E8 expression. Univariate and multivariate analyses revealed that MFG-E8 expression was a statistically significant and independent prognostic factor. Conclusion MFG-E8 expression may serve as a tumour progression marker and can predict an unfavourable prognosis in patients with melanoma.

    Original languageEnglish
    Pages (from-to)506-512
    Number of pages7
    JournalBritish Journal of Dermatology
    Volume165
    Issue number3
    DOIs
    Publication statusPublished - 2011 Sep

    Fingerprint

    Epidermal Growth Factor
    Melanoma
    Survival
    Tumor Biomarkers
    Neoplasms
    Nevi and Melanomas
    Tumor-Infiltrating Lymphocytes
    Immune Tolerance
    Nevus
    Phosphatidylserines
    Phagocytes
    Homeostasis
    Multivariate Analysis
    Eating
    Immunohistochemistry
    Maintenance
    milk fat globule
    Neoplasm Metastasis
    Proteins

    ASJC Scopus subject areas

    • Dermatology

    Cite this

    Expression of milk fat globule epidermal growth factor-VIII may be an indicator of poor prognosis in malignant melanoma. / Oba, J.; Moroi, Y.; Nakahara, T.; Abe, T.; Hagihara, A.; Furue, M.

    In: British Journal of Dermatology, Vol. 165, No. 3, 09.2011, p. 506-512.

    Research output: Contribution to journalArticle

    Oba, J. ; Moroi, Y. ; Nakahara, T. ; Abe, T. ; Hagihara, A. ; Furue, M. / Expression of milk fat globule epidermal growth factor-VIII may be an indicator of poor prognosis in malignant melanoma. In: British Journal of Dermatology. 2011 ; Vol. 165, No. 3. pp. 506-512.
    @article{38458b8af4e749b88bf3476979d471e9,
    title = "Expression of milk fat globule epidermal growth factor-VIII may be an indicator of poor prognosis in malignant melanoma",
    abstract = "Summary Background Milk fat globule epidermal growth factor-VIII (MFG-E8) is a secreted protein that binds phosphatidylserine and promotes apoptotic cell ingestion by phagocytes, mediating the immune tolerance and maintenance of homeostasis. A recent study has shown that MFG-E8 expression in human melanoma is increased with tumour progression; however, the effect of its expression on patient survival has not yet been clarified. Objective To analyse MFG-E8 expression in melanoma, and to determine whether it can serve as a marker for diagnosis, tumour progression and/or prognosis. Methods MFG-E8 expression was examined by immunohistochemistry in 60 primary melanomas, 22 metastatic lesions and 30 benign naevi. The following clinicopathological variables were evaluated: age, gender, histological type, tumour site, Breslow thickness, Clark's level, the presence or absence of ulceration and tumour-infiltrating lymphocytes, and survival periods. Statistical analyses were performed to assess associations and melanoma-specific survival. Results MFG-E8 expression was significantly higher in primary and metastatic melanoma than in naevus. Furthermore, it increased according to tumour progression and metastasis. Patients with MFG-E8 expression in primary tumours had significantly shorter survival periods than those without MFG-E8 expression. Univariate and multivariate analyses revealed that MFG-E8 expression was a statistically significant and independent prognostic factor. Conclusion MFG-E8 expression may serve as a tumour progression marker and can predict an unfavourable prognosis in patients with melanoma.",
    author = "J. Oba and Y. Moroi and T. Nakahara and T. Abe and A. Hagihara and M. Furue",
    year = "2011",
    month = "9",
    doi = "10.1111/j.1365-2133.2011.10409.x",
    language = "English",
    volume = "165",
    pages = "506--512",
    journal = "British Journal of Dermatology",
    issn = "0007-0963",
    publisher = "Wiley-Blackwell",
    number = "3",

    }

    TY - JOUR

    T1 - Expression of milk fat globule epidermal growth factor-VIII may be an indicator of poor prognosis in malignant melanoma

    AU - Oba, J.

    AU - Moroi, Y.

    AU - Nakahara, T.

    AU - Abe, T.

    AU - Hagihara, A.

    AU - Furue, M.

    PY - 2011/9

    Y1 - 2011/9

    N2 - Summary Background Milk fat globule epidermal growth factor-VIII (MFG-E8) is a secreted protein that binds phosphatidylserine and promotes apoptotic cell ingestion by phagocytes, mediating the immune tolerance and maintenance of homeostasis. A recent study has shown that MFG-E8 expression in human melanoma is increased with tumour progression; however, the effect of its expression on patient survival has not yet been clarified. Objective To analyse MFG-E8 expression in melanoma, and to determine whether it can serve as a marker for diagnosis, tumour progression and/or prognosis. Methods MFG-E8 expression was examined by immunohistochemistry in 60 primary melanomas, 22 metastatic lesions and 30 benign naevi. The following clinicopathological variables were evaluated: age, gender, histological type, tumour site, Breslow thickness, Clark's level, the presence or absence of ulceration and tumour-infiltrating lymphocytes, and survival periods. Statistical analyses were performed to assess associations and melanoma-specific survival. Results MFG-E8 expression was significantly higher in primary and metastatic melanoma than in naevus. Furthermore, it increased according to tumour progression and metastasis. Patients with MFG-E8 expression in primary tumours had significantly shorter survival periods than those without MFG-E8 expression. Univariate and multivariate analyses revealed that MFG-E8 expression was a statistically significant and independent prognostic factor. Conclusion MFG-E8 expression may serve as a tumour progression marker and can predict an unfavourable prognosis in patients with melanoma.

    AB - Summary Background Milk fat globule epidermal growth factor-VIII (MFG-E8) is a secreted protein that binds phosphatidylserine and promotes apoptotic cell ingestion by phagocytes, mediating the immune tolerance and maintenance of homeostasis. A recent study has shown that MFG-E8 expression in human melanoma is increased with tumour progression; however, the effect of its expression on patient survival has not yet been clarified. Objective To analyse MFG-E8 expression in melanoma, and to determine whether it can serve as a marker for diagnosis, tumour progression and/or prognosis. Methods MFG-E8 expression was examined by immunohistochemistry in 60 primary melanomas, 22 metastatic lesions and 30 benign naevi. The following clinicopathological variables were evaluated: age, gender, histological type, tumour site, Breslow thickness, Clark's level, the presence or absence of ulceration and tumour-infiltrating lymphocytes, and survival periods. Statistical analyses were performed to assess associations and melanoma-specific survival. Results MFG-E8 expression was significantly higher in primary and metastatic melanoma than in naevus. Furthermore, it increased according to tumour progression and metastasis. Patients with MFG-E8 expression in primary tumours had significantly shorter survival periods than those without MFG-E8 expression. Univariate and multivariate analyses revealed that MFG-E8 expression was a statistically significant and independent prognostic factor. Conclusion MFG-E8 expression may serve as a tumour progression marker and can predict an unfavourable prognosis in patients with melanoma.

    UR - http://www.scopus.com/inward/record.url?scp=80052196437&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=80052196437&partnerID=8YFLogxK

    U2 - 10.1111/j.1365-2133.2011.10409.x

    DO - 10.1111/j.1365-2133.2011.10409.x

    M3 - Article

    C2 - 21574974

    AN - SCOPUS:80052196437

    VL - 165

    SP - 506

    EP - 512

    JO - British Journal of Dermatology

    JF - British Journal of Dermatology

    SN - 0007-0963

    IS - 3

    ER -